Speaker Profile
CEO + Co Founder, Aitia
Biography
Colin Hill is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. He co-founded leading AI biosimulation company Aitita (formally GNS Healthcare) in 2000, and has since served as CEO. In 2020 the company launched the worlds first Virtual Patients beginning in Multiple Myeloma and has since launched Virtual Patients in Prostate Cancer and Alzheimers Disease. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs. Colin previously served on the boards of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company (acquired by Philips in 2021), and PPD Inc. (NASDAQ: PPD), a leading global contract research organization (acquired by Thermo in 2021).
Talk
Causal AI and Digital Twins: BuildingTranslational Platforms for First-in-Class TargetDiscovery
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
Gad Getz, Broad Institute
Alex Morgan, Khosla Ventures
PMWC Award Ceremony Honoree
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Keynote
• Vinod Khosla, Khosla Ventures
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Illuminating Drug Discovery: AI Models That Learn From Biology
• Erwin Estigarribia, HEADLAMP Health
Harmonizing the Data Economy: Enabling AI Across Institutions and Therapeutic Areas
• Noah Nasser, Datma
Can AI Really Create the Next Blockbuster Drug?
• James Zou, Stanford
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
Closing the Loop: AI in the Messy Middle of Drug Development
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald / MIT
Is AI the New Drug?
• Michael J. Kahana, Nia Therapeutics
